MedPath

MRI Screening of Placenta Adhesion Abnormalities

Not Applicable
Recruiting
Conditions
Placenta; Implantation
Interventions
Device: MRI
Registration Number
NCT04328532
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes, especially in case of incidental discovery during delivery that increase the risk of intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been increasingly performed in the case of inconclusive sonographic findings. However, standard morphological MRI sequences appear as insufficient to improve the sensitivity and specificity values for detecting PAA, while quantitative MRI may be more efficient.

The main objective of this study is to characterize the diagnostic performance of quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2\*) reflecting placental perfusion and/or oxygenation at high field, without injection of gadolinium-based agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of gestation with risk factors for PPA.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
71
Inclusion Criteria
  • Pregnant participant between 30 and 38 weeks of gestation,
  • Age ≥18 years old,
  • Participant who completed the preliminary medical examination,
  • Participant who has received full information about the organization of the research and has signed her informed consent.
  • Participant planning to give birth at CHRU of Nancy
  • Participant presenting risk factors for PAA : low-lying or covering placenta or in front of the uterine scar.
Exclusion Criteria
  • Multiple pregnancy,
  • Participant presenting at least one contraindication or restriction to performing an MRI as described in the protocol, in accordance with the current recommendations,
  • Participant unable to understand or follow study procedure,
  • Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the Public Health Code.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pregnancy with risk factors for PPAMRI-
Primary Outcome Measures
NameTimeMethod
Area under the ROC curve of the T2* relaxation time mean valueThrough study completion, an average of 6 months
Area under the ROC curve of the T2 relaxation time mean valueThrough study completion, an average of 6 months
Area under the ROC curve of the Apparent Diffusion Coefficient mean valueThrough study completion, an average of 6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Centre Hospitalier Régional Universitaire de Nancy

🇫🇷

Vandœuvre-lès-Nancy, France

© Copyright 2025. All Rights Reserved by MedPath